Coverage or Efficacy: Which Factor is the Most Influential for Reducing Varicella with Routine Childhood Vaccination in Italy? by Sauboin, C et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A683
suggest that PIM is a cost-effective treatment strategy compared to OTT for HIV-1 
infected patients who have achieved sustained virological suppression.
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the treAtmeNt of hePAtItIs C IN the heAlth system of extremAdurA 
(ses)
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Objectives: Evaluate the cost associated with the ADRs from the use of boceprevir 
(BOC) or telaprevir (TLP) in patients treated with protease inhibitors (PI) in the 
SES. MethOds: A multicenter observational study of cohort ITT, extracting the nec-
essary data from the information systems of SES, from September 2012 to December 
2013, for patients treated with TLP or BOC was performed. Those co-infected patients 
(HIV or HBV), in liver transplant or with history of hepatocellular carcinoma were 
excluded. ADRs assessed were alopecia, fever, retinitis, itching, weight loss, rash, 
thrombosis, neutropenia, hemorrhoids, stomach pain, amenorrhoea, arthralgia, 
anxiety and the number of infiltrated blood received by patients. To assess the 
pharmaceutical cost of ADRs the retail price + VAT at Official List were taken, and to 
other public health costs SSPE prices, the NHS and records of unit costs were taken 
also. Results: Withdrawals caused by ADRs were higher for TLP (12.2% vs 8.1%, 
p = 0.09), frequency of pruriginous erythema (44.9% vs 4%, p < 0.001) and anemia 
(69.4 % vs. 52%, p = 0.142). For BOC, there were higher percentages of dysgeusia (16% 
vs. 0%, p = 0.011), and neutropenia (52% vs. 24.5%, p = 0.018). The results showed a 
significant difference between the treatment cost per patient associated with ADRs 
caused by BOC (€ 5,896) compared to the TLP (€ 11,234), for 34.7 weeks (BOC) and 25.9 
weeks (TLP). cOnclusiOns: In view of the results obtained, it shows that means a 
lower costs for the health system ―in the treatment of ADRs due to the use of PI in 
patients with hepatitis C― patients receiving BOC versus TLP. Postmarketing obser-
vational studies are needed to determine the actual efficacy and safety of new drugs.
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PrImAry CAre PhysICIANs IN AN INterferoN-free world: Could sAfer, 
more efeCtIve orAl hePAtItIs C therAPIes leAd to ImProved outComes 
through eduCAtIoN ANd PCP-PresCrIbed treAtmeNt?
Levine-Wilkinson S.R., Holman D.W., Cummings H.E.
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Objectives: Hepatitis C virus (HCV) treatments have been improved by the 
availability of highly effective and well-tolerated interferon-free therapies. This 
study probes the impact of such therapies on the role of primary care physicians 
(PCPs) in diagnosis, referral, and treatment of HCV patients who have historically 
been treated by gastroenterologists and hepatologists. MethOds: In the U.S., 
100 PCPs, 51 specialists (44 gastroenterologists, 7 hepatologists), and 30 Managed 
Care Organization (MCO) pharmacy directors/medical directors (PDs/MDs) were 
surveyed to assess PCP knowledge of and involvement in HCV diagnosis and 
screening, referral patterns, and treatment options. Results: Survey results 
identify referral to specialists as a notable barrier to accessing care. Some 77% 
of PCPs who follow-up with patients they refer to HCV specialists estimate that 
24% are lost to follow-up. Similarly, 73% of specialists report having PCP-referred 
patients who missed their exam, and these specialists estimate that 15% of all PCP-
referred patients “drop off”. In anticipation of multiple new HCV therapies reach-
ing the major markets, several professional societies have collaborated to develop 
expert-curated, regularly updated guidelines providing clinical recommendations 
for diagnosing and treating HCV patients (www. hcvguidelines. org). Among sur-
veyed PCPs, 74% were unaware of these guidelines; however, once informed, 63% 
of all PCP respondents indicated greater comfort with prescribing treatments rec-
ommended by these guidelines. Furthermore, 63% of MCO PDs/MDs and 98% of 
HCV specialists surveyed reported feeling more comfortable with PCPs prescribing 
these recommended treatments. cOnclusiOns: The substantial decline in the 
cascade of care from PCP referrals to specialists suggests that educating PCPs on 
new interferon-therapies presents an opportunity to maximize retention in care 
and accelerate efforts to identify undiagnosed cases. Survey responses from PCPs, 
as well as specialists, and MCO PDs/MDs suggest that practical, regularly updated 
clinical guidelines prepared by international experts could provide a common 
framework for educational outreach efforts to PCPs.
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Objectives: Policymakers may have a concern that a long time interval between 
two doses, partial efficacy and potential waning after the first dose of varicella 
vaccination would reduce the impact of a universal childhood varicella immuni-
zation program. The objective of this study is to determine the potential impact 
and relative weight of 2 key factors: (1) coverage and (2) vaccine efficacy (VE) of 
the first dose of varicella vaccination (VE-D1) in the context of long term interval 
between two doses on varicella epidemiology in Italy. MethOds: An age-structured 
dynamic transmission model is adapted and fitted to the seroprevalence of varicella 
in Italy in absence of vaccination. Vaccination is introduced with 1- and 2-dose VE, 
with long time interval between 2 doses (given at 13 months and 6 years of age). 
Several scenarios are tested including 2 levels of VE-D1 (65%/75%) and 3 coverage 
levels (95%/80%, 85%/70%, 75%/60%, respectively). Efficacy post-dose 2 is fixed at 
95%. Results: For a vaccine coverage of 95%/80%, the reduction in number of vari-
cella cases compared with the absence of vaccination for 75% and 65% VE-D1 was 
respectively 89.2%/87.5% by year 30, and 78.9%/74.6% by year 80 after vaccination 
program initiation. For a vaccine coverage of 85%/70%, the reduction in number of 
systematic differences, and conformity to malaria treatment policy, in terms of 
the use of ACT, accuracy of diagnosis, concomitant medication and cost of medi-
cation. Results: 2,171 patients’ records were analyzed. 986 (46%) were sent for 
laboratory confirmation using microscopy, out of which only 45% tested positive. 
Majority of prescriptions, 54% was on the basis of presumptive treatment. 58% of 
slide negative results received antimalarials. Gender disparity was significant; 1207 
(56%) females, 942 (43%) males. 93% of prescriptions contained ACTs with AL as the 
most frequently prescribed antimalarial drug. Monotherapy accounted for 7% of 
the prescriptions. 97% (1722) of prescriptions received at least one co-medication, 
mostly analgesics, vitamin preparations and antibiotics. Antibiotics were given to 
50% of patients, with children under five most likely to be co-prescribed antibiot-
ics. Overall, median cost of medication was US$7.34 (US$0.16 – 262.78) per case. 
There were significant variations in treatment practices between the two facili-
ties. cOnclusiOns: Evidence suggest high rate of compliance to policy on the 
use of ACT as first line treatment for uncomplicated malaria but there is significant 
scope for improved diagnosis and prescription to enhance accuracy of treatment 
and reduced wastages, especially at the medical center. Regular updates of providers 
on appropriate practices are needed to improve adherence to treatment guidelines 
for enhanced efficiency of malaria treatment in Nigeria.
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Objectives: To describe real-world treatment patterns, health care resource use, 
and opportunities for early switch (ES) from intravenous (IV) to oral antibiotics 
and early discharge (ED) for patients hospitalized in the United Arab Emirates 
(UAE) with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infections (cSSTIs). MethOds: This retrospective observational 
medical chart review study enrolled physicians from four UAE sites to collect data 
for 24 total patients with documented MRSA cSSTI, hospitalized between July 2010-
June 2011, and discharged alive by July 2011. Data include clinical characteristics 
and outcomes, hospital length of stay (LOS), MRSA-targeted IV and oral antibiotic 
use and ES and ED eligibility using literature-based and expert-validated crite-
ria. Results: For all patients, the actual length of MRSA-active treatment was 
10.8±7 days, with 9.8±6.6 days of IV therapy, and mean LOS 13.9±9.3 days. The most 
frequent initial MRSA-active therapies used were vancomycin (33.3%), linezolid 
(16.7%), and clindamycin (16.7%). Five patients (20.8%) were switched from IV to 
oral antibiotics while inpatient. Eight patients were discharged with MRSA-active 
antibiotics, with linezolid prescribed most frequently (n= 3; 37.5%). Fifteen patients 
(62.5%) met ES criteria and potentially could have discontinued IV therapy 8.3±6.0 
days sooner. Eight patients (33.3%) met ED criteria and potentially could have 
been discharged 10.9±5.8 days earlier. Assuming an average cost of 2,691 dirhams 
($575)/bed day in the UAE, the total savings would be 29,332 dirhams ($6,268) in 
bed-day cost savings realized per ED-eligible patient. cOnclusiOns: While one 
fifth of patients were switched from IV to oral antibiotics in the UAE, there were 
clear opportunities for further optimization of health care resources. Over half of 
UAE patients hospitalized for MRSA cSSTI could be eligible for ES and one-third 
eligible for ED opportunities, resulting in the potential for a substantial reduction 
in IV days and bed days.
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PAtIeNts
Oddershede L.1, Walker S.2, Paton N.3, Stöhr W.3, Dunn D.3, Sculpher M.J.2
1Aalborg University, Aalborg East, Denmark, 2University of York, Heslington, York, UK, 3University 
College London, London, UK
Objectives: To estimate the cost-effectiveness of a strategy of switching the 
antiretroviral therapy (ART) to protease inhibitor monotherapy (PIM) with prompt 
return to combination therapy in the event of viral load rebound compared to con-
tinuing the ongoing triple therapy (OTT) in the long-term management of HIV-1 
infected patients. MethOds: Within trial cost-effectiveness analysis and modelling 
of life-time cost-effectiveness based on a randomised controlled trial of Protease 
Inhibitor monotherapy Versus Ongoing Triple-therapy (PIVOT). The setting was 
HIV outpatient care in the UK National Health Service and the trial involved 587 
patients, aged 18 years or more, who achieved sustained virological suppression 
and have a CD4+ cell count > 100 cells/mm3. Outcomes were NHS costs (2012 UK 
Pounds Sterling) and quality-adjusted life-years (QALY) with comparative results 
presented as incremental cost-effectiveness ratios (ICERs). Results: Overall, PIM 
was cost-effective compared to OTT. PIM was cost-saving due to large savings in 
the ART drug costs while being no less effective in terms of QALYs in the within 
trial analysis and only marginally less effective with modelling. In the base-case 
within-trial analysis, the incremental total cost per patient was -£6,424.11 (95% 
confidence interval: -£7,418.84 to -£5,429.38) and the incremental QALY was 0.0051 
(95% confidence interval: -0.0479 to 0.0582) making PIM dominant compared to 
OTT. Multiple sensitivity analyses were conducted to assess the importance of 
assumptions surrounding drug costs, missing data, trial protocol driven costs and 
mortality. In all sensitivity analyses, PIM was cost-saving and no marked difference 
in QALY was observed. Modelling of life time costs and QALYs showed significant 
cost-savings and marginally less effectiveness such that switching to PIM appeared 
cost-effective at accepted cost-effectiveness thresholds. cOnclusiOns: The results 
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for influenza vaccination, ILI symptoms, time off work/education, and HCRU. 
Transmission of ILI from children to adults was estimated. Descriptive statistics 
were used. Results: Across 938 participants/households there were 1895 adults 
mean age 40.6 years, 52.7% females; 1695 children mean age 8.7 years, 46.8% females. 
91/306 adult ILI incidences were related to a child ILI (29.7%, 95%CI:26.5%-33.0%). 69 
of these (75.8%, 95%CI:60.3%-91.3%) had symptom duration> 3 days, 31/86 employed 
(36.0%; 95%CI:28.5%-43.6%) reported taking time off work with 22/31 (71.0%; 
95%CI:46.2%-95.8%) taking ≥ 2 days off. 13/91 (14.3%; 95%CI:11.5%-17.1%) had general 
practice (GP) visits, 5/91 (5.5%; 95%CI:4.5%-6.5%) had GP telephone consultations, 
6/91 (6.6%; 95%CI:5.3%-7.8%) received prescriptions, 76/91 (83.5%; 95%CI:66.5-100.6%) 
used over the counter (OTC) medications because of their ILI. 67 adults reported time 
off because of child ILIs (310 incidences); 30/67 (44.8%; 95%CI:34.2%-55.4%) taking 
≥ 2 days. This represents 67 adults/152 working adults (44.1%; 95%CI:37.2%-51.0%) 
in the child ILI households. 180/310 (58.1%; 95%CI:51.7%-64.5%) of total child ILIs 
had time off education, 81/180 (45.0%; 95%CI:38.5%-51.5%%) taking ≥ 3 days. 59/310 
(19.0%; 95%CI:17.0%-21.1%) had GP visits, 22/310 (7.1%; 95%CI:6.4%-7.8%) had GP 
telephone consultations, 48/310 (15.5%; 95%CI:13.8%-17.2%) received prescriptions, 
234/310 (75.5%; 95%CI:67.1-83.8%) used OTC medications. cOnclusiOns: Based 
on survey, approximately 1/3 of adult ILIs were related to prior household child 
ILI. ILI in a household often required absence from work and ILI in children often 
resulted in time off education. GP visits were the most frequent burden to the 
National Health Service.
PIN117
CoPINg wIth methICIllIN resIstANt stAPhyloCoCCus Aureus (mrsA) IN 
germAN rehAbIlItAtIoN CeNters – Are the INCeNtIves APProPrIAte?
Claus F., Ried W.
University of Greifswald, Greifswald, Germany
Objectives: Patients colonized with multidrug-resistant organisms, especially 
Methicillin resistant Staphylococcus aureus (MRSA), impose a risk on other 
patients and on health care professionals. In addition, they will suffer from sub-
stantial health problems when getting an infection. This contribution examines 
the incentives of German rehabilitation centers to implement screening strategies 
to stem nosocomial infections and the spread of MRSA. MethOds: Relying on a 
decision tree analysis, the expected health care cost per capita is calculated for 
three strategies: (i) general screening, (ii) risk-based screening, both on admission, 
and (iii) no screening at all. Parameters are taken from the published literature. 
To handle uncertainty, multivariate sensitivity analyses are performed. Results: 
From the perspective of a rehabilitation center, the third strategy yields the lowest 
expected cost while the first one causes the highest cost. This ordering is robust with 
respect to sensitivity analysis. Thus, cost savings due to a lower number of MRSA 
infections are not sufficient to offset the cost of the test and further prevention 
measures applied to individuals with a positive result. cOnclusiOns: In Germany, 
rehabilitation centers are reimbursed by daily rates. In particular, they receive no 
extra fees for prevention measures. As our analysis demonstrates, this implies the 
incentive to implement MRSA screening to be too weak. Hence, MRSA prevention 
measures that would be beneficial to society will not be undertaken. However, our 
results can be used to indicate changes in the remuneration system that would 
provide rehabilitation centers with an appropriate incentive for MRSA prevention. 
Moreover, hygiene regulations enacted very recently (MedHygVO), in the light of 
our analysis, can be interpreted in a similar manner due to the requirement of a 
stricter hygiene regimen.
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Objectives: In 2008, the Centers for Medicare and Medicaid Services discontin-
ued reimbursement for health care associated infections (HAIs) not reported to be 
present-on-admission (POA). The study objectives were to examine: (1) the impact 
of this reimbursement change on hospital-level HAI rates; and (2) the differences 
in total direct medical costs and length of stay (LOS) between patients with HAI 
(cases) and without HAI (controls). MethOds: We conducted a retrospective, 
interrupted time series analysis using the Nationwide Inpatient Sample obtained 
from the Health care Cost and Utilization Project database for years 2006 to 2010. 
The primary outcome was diagnosis of HAI, identified based on ICD-9-CM codes 
for sepsis, pneumonia, surgical site infections, catheter-associated urinary tract 
infections or blood stream infections from a pool of “at-risk” patients defined as ≥ 
18 years of age, without a diagnosis of cancer, HIV/AIDS or immunocompromised 
condition. Patients with an LOS ≤ 2 days were excluded to avoid inclusion of patients 
with pre-existing infections. Differences in total direct medical costs and LOS of 
propensity score-matched cases and controls were assessed using Wilcoxon signed-
rank tests. Results: The HAI rate was higher in the “at-risk” population (12.95 vs. 
2.83 per 100 admissions) than in the total inpatient population, ≥ 18 years of age. 
Discontinuation of reimbursement for HAI was associated with a 0.37 point (-0.375, 
p = 0.0064) decrease in HAI rate per 100 admissions for “at-risk” patients. Compared 
to controls, cases had significantly higher mean annual total direct medical costs 
($15,313 ± 17,470 vs. $21,561 ± 31,718, p< 0.0001) and a higher mean LOS (7.1 ± 6.5 
vs. 10.2 ± 11.3 days, p< 0.0001). cOnclusiOns: Total direct medical costs and LOS 
are higher for patients with HAI compared to those without HAI. Policy changes in 
the reimbursement of HAI cases made in 2008 showed a reduction in the rate of 
HAIs in the “at-risk” population.
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stewArdshIP ProgrAm IN A medICAl CeNter IN tAIwAN
Huang L., Kuo C., Lin Y., Chen Y., Wong Y., Lin Y.
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varicella cases for 75% and 65% VE-D1 was respectively 73.9%/71.3% by year 30 and 
65.0%/61.6% by year 80. When coverage was 75%/60%, the reduction in number of 
varicella cases was 60.2%/58.1% by year 30 and 55.0%/52.5% by year 80 for VE-D1 of 
75% and 65%, respectively. cOnclusiOns: The coverage of varicella vaccination is 
an important factor affecting the number of varicella cases when long term interval 
between two doses is considered. This is a more influential factor on predicted cases 
than the first dose efficacy.
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Objectives: To examine herpes zoster-related health care resource utilization in 
hematologic (HM) or solid tumor malignancy (STM) patients seeking care at pri-
mary-care practices in 5 European countries. MethOds: Longitudinal primary-
care EMR databases (Cegedim Strategic Data) in France, Italy, Germany, Spain, and 
United Kingdom (UK) were analyzed retrospectively (2007-2012). Patients with HM 
or STM diagnoses were followed for a subsequent first herpes zoster (HZ) diagno-
sis (index event). HZ patients were matched with non-HZ (HM and STM) patients 
using propensity scores based on demographics and relevant clinical characteris-
tics. Patients were observed for 6 months pre-index (baseline) and 6 months post-
index. Demographics, comorbidities, pharmacotherapy, and health care resource 
utilization (office visits, specialty referrals, laboratory tests, and prescriptions) were 
reported with statistical significance set at p≤ 0.05. Results: HZ patients meeting 
selection criteria across all 5 countries included 907 HM and 4317 STM. Mean ages 
ranged 64.8±15.5 (Italy-HM) to 71.8±11.5 (France-STM); female gender varied for HM 
from 49% (UK) to 58% (Germany), and STM 56% (UK) to 63% (France). Case and control 
populations were well balanced at baseline. Office visits per patient were signifi-
cantly higher post-index for HZ cohorts across all countries and malignancy types 
(except Spain HM), ranging from 0.5 more visits (Spain-STM, p= 0.009,) to 2.8 more 
(UK-HM, p< 0.001). Significantly more HZ patients had post-index specialty referrals 
(France-STM, 2.6% more, p= 0.05; Germany-STM, 4.8% more, p= 0.012), and signifi-
cantly more HZ patients received prescriptions post-index in all cohorts across all 
countries, varying from 19.2% more patients (Spain-STM, p< 0.001,) to 47.3% (UK-HM, 
p< 0.001). Significantly more HZ patients received laboratory testing, ranging from 
3.2% more patients (Italy-STM, p= 0.006,) to 11.4% (UK-HM, p= 0.003). cOnclusiOns: 
Significantly higher health care resource use was incurred by HZ-afflicted HM and 
STM patients within 6 months of HZ diagnosis for office visits, specialty referrals, 
laboratory testing, and outpatient prescribing compared with matched controls 
across 5 European countries.
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Objectives: Information on the pattern of health services use by HIV patients is 
required to effectively plan services, particularly in light of increasing non-infec-
tious chronic diseases in this population. This study examined the use of inpatient, 
outpatient, and emergency department (ED) services by HIV positive patients who 
attended Cork University Hospital (CUH) for HIV care in 2012. MethOds: All pub-
lic HIV patients who attended CUH for inpatient or outpatient care in 2012 were 
identified using an existing clinical database. Data on outpatient appointments 
by speciality (excluding dialysis), ED visits and inpatient episodes were extracted 
from the hospital information system. Patients with no attendance between Jul-
Dec were censored at the month of last visit. Results: Data were extracted on 
328 patients (3642 patient-months), 1434 outpatient visits (1180 Infectious Disease 
(ID), 254 other), 100 ED visits (58 patients) and 74 inpatient episodes (51 patients). 
Patients had a median of 3 ID outpatient visits (range 0-12), 26% of patients also 
attended other outpatient specialties (median 2, range 1-22). On multivariate 
analysis being more recently diagnosed, and being on ART but not suppressed, or 
starting/stopping ART in 2012 were associated with increased outpatient ID visits, 
while age > 50 years was associated with fewer outpatient ID visits. Those diag-
nosed 2003-2007 and 2008-2011 had significantly more outpatient non-ID visits 
while late diagnosis was associated with fewer non-ID visits. Use of ED services 
was positively associated with unknown risk factor and being diagnosed in 2012. 
Use of inpatient services was positively associated with diagnosis in 2012 and 
negatively associated with a minimum CD4 count ≥ 350 cells/μ l. cOnclusiOns: 
These data provide baseline information on the utilisation rates of ID and other 
specialities by HIV positive patients. Such data are useful for identifying factors 
which could be targeted for quality improvement interventions as well as for 
estimating future service requirements.
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Objectives: To evaluate the impact of child ILI on working adults’ health, pro-
ductivity and health care resource use (HCRU); and to evaluate ILI’s impact on the 
children. MethOds: Participants ≥ 18 years, full or part time working and with 
minimum one child ≤ 17 years residing in household were recruited nationally 
(UK) for this online survey between October 2012 and May 2013. Demographics, 
employment status, morbidities and influenza vaccination history were collected 
for all household members. During follow-up, households were surveyed fortnightly 
